

Case Docket No. UC067.0024 Date: September 26, 2002

I hereby certify that this correspondence and all marked attachments are being deposited with the United States

Postal Service as first class mail in an envelope addressed

to: United States Patent and Trademark Office, P.O. 2327,

September 26, 2002

(Date)

Arlington, VA 22202, on

Page

In re application of

Saxon et al.

App. No.

09/847,208

Filed

: May 1, 2001

For

FUSION MOLECULES AND

TREATMENT OF IgE-MEDIATED

ALLERGIC DISEASES

Examiner

Phuong N. Huynh

Art Unit

1644

UNITED STATES PATENT AND TRADEMARK OFFICE BOX AF P.O. Box 2327

Arlington, VA 22202

Sir:

Transmitted herewith is:

- (X) An Amendment and Response to Final Office Action in the above-identified application.
- (X) An article referenced in the above documents entitled, "A Novel Human Immunoglobin Fcγ-Fcε Bifunctional Fusion Protein Inhibits FcεRI-mediated Degranulation", Zhu *et al.*, *Nature Medicine*, Volume 8 (5): 518-521 (2002).

The fee has been calculated as shown below:

CLAIMS AS FILED							
	CLAIMS REMAINING AFTER AMENDMENT	<u>, L</u>	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE	
Total Claims	19		72	= 0 ×	\$9	= \$0	
Independent Claims	2		5	= 0 ×	\$42	= \$0	
If application has bee dependent claim(s),		itain multiple	, <u></u>	.	\$140	= \$0	
Time Extension Fee					· · · · · · · · · · · · · · · · · · ·	\$0	
	<u> </u>				OITIONAL FEE MENDMENT	\$0	


Case Docket No. UC067.002A Date: September 26, 2002

Page 2

- (X) Return prepaid postcard.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Ginger R. Dreger Registration No. 33,055 Attorney of Record Customer No. 20,995

W:\DOCS\EJD\EJD-1385.DOC



OCT O	DEMA	THE UNITED STATES PATENT AND TR	RADEMARK OFFICE THE TOP TO THE TO
Applicant	:	Saxon et al.	Group Art Unit 1644
Appl. No.	:	09/847,208	I hereby certify that this correspondence and all marked attachments are being deposited with the
Filed	:	May 1, 2001	United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on
For	:	FUSION MOLECULES AND TREATMENT OF IgE-MEDIATED ALLERGIC DISEASES)	(Date) (Singer R. Dreger, Reg. No. 33,055
Examiner	:	Phuong N. Huynh)	

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The present communication is responsive to the Final Office Action mailed on July 2, 2002 (Paper No. 12). Applicants respectfully request reconsideration of the application in view of the following Amendment and Remarks.

AMENDMENT

In accordance with 37 C.F.R. § 1.121, please amend the application as follows.

IN THE CLAIMS:

Please cancel Claims 1-6, 22-27, 29-30, 40-54 and 73-76.

Please insert new claims 77-95, which read as follows:

77. An isolated fusion molecule comprising an IgG heavy chain constant (New) region sequence capable of binding to an IgG inhibitory receptor functionally connected to an IgE heavy chain constant region sequence capable of binding to an IgE receptor.